Skip to main content
TMDX
NASDAQ Industrial Applications And Services

TransMedics Q2 Revenue Beats, But Net Income Drops 58% on Surging R&D Spend; FY26 Guidance Raised

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$82.01
Mkt Cap
$2.791B
52W Low
$60.105
52W High
$156
52W Position info
36% above low
Off High info
47% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

TMDX sits 36% above its 52-week low of $60.105.

Summary

TransMedics reported Q2 revenue of $189.9M (+21% YoY), beating estimates, but net income fell 58% to $14.7M due to a 49% surge in operating expenses. FY26 revenue guidance was raised to $737M-$757M.

Updates

  1. · Reuters — Gross margin compressed to 60% due to a shift toward service revenue and temporary product-cost headwinds. The revenue beat was driven by increased OCS utilization in liver and heart transplants.


Key Events · Earnings and Guidance · TMDX

  • Q2 Revenue Beats, Net Income Misses

    Revenue of $189.9M exceeded the $183.64M consensus, but net income fell 58% YoY to $14.7M ($0.41 diluted EPS) as operating expenses surged 49% to $89.5M.

  • FY26 Guidance Raised at Low End

    Full-year 2026 revenue guidance increased to $737M-$757M (from $727M-$757M), implying 22-25% growth, excluding PAD Aviation and clinical trial revenue.

  • Margin Compression from Strategic Investments

    Operating margin contracted to 12.5% from 23.2% a year ago, driven by planned R&D and infrastructure spending on OCS Kidney, Gen 3.0, and logistics.

  • PAD Aviation Investment Completed

    On July 1, 2026, TransMedics completed its strategic investment in PAD Aviation, a German private aviation operator, to build a dedicated organ transplant air logistics network in Europe.


Analysis · TMDX · Industrial Applications And Services

Record Q2 revenue of $189.9 million topped consensus, yet net income tumbled to $14.7 million as operating expenses surged 49%—a reflection of heavy investment in OCS Kidney, Gen 3.0, and clinical programs. While the company raised the low end of its full-year revenue guidance to $737 million, signaling confidence in demand, margin compression is the clear trade-off. Adding a governance overhang, the concurrent 10-Q disclosed a material weakness in internal controls.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TMDX was trading at $82.01 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $60.11 to $156.00. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TMDX - Latest Insights

TMDX
Nov 06, 2026, 2:06 PM EST
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $87.77
Real-time Price: $95.08 info
Change: +$7.31 (+8%) info
Market Cap: $3.302B info
TMDX
Nov 05, 2026, 4:10 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $82.50
Real-time Price: $95.08 info
Change: +$12.58 (+15%) info
Market Cap: $3.302B info
TMDX
Nov 05, 2026, 4:02 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $76.80
Real-time Price: $95.08 info
Change: +$18.28 (+24%) info
Market Cap: $3.302B info
TMDX
Nov 05, 2026, 4:02 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $68.97
Real-time Price: $95.08 info
Change: +$26.11 (+38%) info
Market Cap: $3.302B info
TMDX
Aug 04, 2026, 4:44 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $88.04
Real-time Price: $95.08 info
Change: +$7.03 (+8%) info
Market Cap: $3.302B info